多西紫杉醇联合顺铂治疗晚期非小细胞肺癌的疗效

Clinical Research for Docetaxel Plus Cisplatin in Untreated Adwanced Non-small Cell Lung Cancer

目的评价多西紫杉醇联合顺铂治疗晚期非小细胞肺癌的疗效及不良反应,探讨影响化疗后生存的临床因素。方法病理学确诊的晚期非小细胞肺癌患者41例,给予多西紫杉醇75mg/m2静脉滴注,第1天,顺铂75mg/m2静脉滴注,第2～4天,21天为一个周期,完成两个周期以上化疗的患者评价疗效及不良反应。采用Kaplan-Meier法分析生存情况,Log-rank法进行单因素检验,Cox回归进行多因素分析。结果总有效率为29.3%,中位生存期10.3月。主要不良反应为骨髓抑制、恶心呕吐及脱发,大多数患者耐受性良好。单因素检验及Cox回归分析均显示:对于体能状态评分较好的患者(PS≤2分),影响生存期的主要因素有TNM分期、体重减轻及化疗疗效(P<0.05),而与患者的性别、年龄、病理类型关系不大(P>0.05)。结论多西紫杉醇联合顺铂治疗晚期非小细胞肺癌疗效好,不良反应小,耐受性较好,值得临床进一步研究应用,而化疗的疗效,肿瘤的TNM分期及体重减轻均对患者的预后有着重要的影响。

Objective To evaluate efficacy effects and toxicities of Docetaxel plus Cisplatin for patients with advanced non-small cell lung cancer and approach clinical factors which can affect the survival. MethodsForty-one patients with advanced non-small cell lung cancer were received docetaxel 75mg/m2 on day 1 and cisplatin 75mg/m2 on days 2 to 4.The cycle of regimen was repeated every 3 weeks.Response and toxicity were evaluated in patients who completed two cycles of chemotherapy at least. Results[KG1] The overall response rate was 29.3% and the median survival time was 10.3 months.The predominant toxicities were inhibition of bone marrow,nausea,vomiting and baldness.Most of patients were well-tolerated.Log-rank test and Cox regression appear that the efficacy,TNM stages and weight of tumor decreases are important factors for prognosis of patients with good physical performance and gender.Age and pathological type are less important factors. Conclusion Among the chemotherapy methods for advanced non-small cell lung cancer,Docetaxel plus Cisplatin has significant response rate,and its toxicity is well-tolerated,which worths advanced study and applying in clinical works.The therapeutic effects,TNM stages of tumor and weight decreases are important factors for prognosis.